×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Coronavirus | Financial Markets | Health Topics | Infrastructure | Money | Vaccines | COVID-19 omicron vaccine

COVID-19 Vaccine Makers Start Work on Omicron-Tailored Shots

Moderna
BioNTech, Johnson & Johnson and Moderna (COVID-19 vaccine vial pictured) are among the first pharmaceutical companies to announce that they are working on a vaccine specific to the omicron variant from South Africa. (Dreamstime)

Monday, 29 November 2021 09:34 AM

BioNTech, Moderna and Johnson & Johnson are working on vaccines that specifically target omicron in case their existing shots are not effective against the new coronavirus variant, the companies said on Monday.

The variant's emergence has triggered a strong global response as countries worried that it could spread fast even in vaccinated populations impose travel curbs and other restrictions.

BioNTech SE said it had started work on a vaccine tailored to omicron, along with partner Pfizer.

Meanwhile, Moderna Inc said it could take months to begin shipping such a vaccine, Chief Executive Officer Stéphane Bancel told CNBC.

Bancel said the effectiveness of existing COVID-19 vaccines against the variant was currently not known, adding there should be more clarity in about two weeks.

Johnson & Johnson is also evaluating the effectiveness of its COVID-19 vaccine against omicron, while also pursuing a vaccine specific to the variant.

"We have begun work to design and develop a new vaccine against omicron and will rapidly progress it into clinical studies if needed," said Mathai Mammen, global head of research for J&J's pharmaceuticals unit.

A top South African infectious disease expert said omicron appears to be more transmissible than previous variants, including to people with immunity from vaccination or prior infection.

© 2022 Thomson/Reuters. All rights reserved.


StreetTalk
BioNTech, Moderna and Johnson & Johnson are working on vaccines that specifically target omicron in case their existing shots are not effective against the new coronavirus variant, the companies said on Monday.
COVID-19 omicron vaccine, BioNTech, Moderna, J&J
206
2021-34-29
Monday, 29 November 2021 09:34 AM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved